Shionogi Inc. is the U.S. subsidiary of a 141-year-old global pharmaceutical company with headquarters in Osaka, Japan. We’re dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs.
An Opportunity Pipeline
Our world-class research and cutting-edge medical technologies advance innovative therapies and support our focus on delivering revolutionary new products to patients.
Our Research
A Culture of Collaboration
We believe that partnering accelerates our goal of delivering life-saving new therapies to underserved patients. We seek to tailor commercial collaborations to maximize the potential of innovative new therapies.
Partnering Opportunities
Latest News
-
Nov. 14, 2019
FETROJA® (cefiderocol) Approved by the FDA for Treatment of Complicated Urinary Tract Infections (cUTI) in Adult Patients with Limited or No Alternative Treatment Options
-
Oct. 16, 2019
U.S. FDA Advisory Committee Recommends Approval of Cefiderocol for Treatment of Complicated Urinary Tract Infections
-
Oct. 2, 2019
Shionogi Reports Positive Results from Cefiderocol Phase III Study in Adults with Pneumonia Caused by Gram-negative Pathogens
Work With Us
Collaboration is central to who we are and how we work. We combine the spirit and nimbleness of an entrepreneurial culture with the resources of a global company.
Career Opportunities